European Society of Medical Oncology 2017 Congress - X4 Pharmaceuticals

European Society of Medical Oncology 2017 Congress

European Society of Medical Oncology 2017 Congress

September 2017

A Phase 1 Dose Finding Study of X4P-001 (An Oral CXCR4 Inhibitor) and Axitinib in Patients with Advanced Renal Cell Carcinoma

© 2023 X4 Pharmaceuticals, Inc. All rights reserved. Terms of Use | Privacy Policy